Open Access

Anticancer activity of bergenin against cervical cancer cells involves apoptosis, cell cycle arrest, inhibition of cell migration and the STAT3 signalling pathway

Retraction in: /10.3892/etm.2021.10085

  • Authors:
    • Xingyuan Shi
    • Manman Xu
    • Kai Luo
    • Wenjin Huang
    • Hongwei Yu
    • Tongchong Zhou
  • View Affiliations

  • Published online on: March 13, 2019     https://doi.org/10.3892/etm.2019.7380
  • Pages: 3525-3529
  • Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Bergenin is a secondary metabolite that may be primarily isolated from Bergenia species. Although it has been found to exhibit significant biological activities, the anticancer activity of bergenin against cervical cancer cells has not been explored. The present study was designed to evaluate the anticancer effects of bergenin on HeLa cervical cancer cells. The results showed that bergenin reduced the cell viability of the HeLa cervical cancer cells in a dose‑dependent pattern. However, the anticancer effects of bergenin were found to be comparatively lower on the normal cervical cells. Furthermore, the anticancer effects of bergenin were primarily found to be due to induction of apoptosis in the HeLa cervical cancer cells. Notably, bergenin also enhanced the expression of Bax and decreased the expression of Bcl‑2. WThe effect of bergenin on cell cycle phase distribution of HeLa cells was also investigated and it was found that bergenin could induce G0/G1 cell cycle arrest. Furthermore, bergenin could also inhibit the migration of HeLa cancer cells as well as the phosphorylation of STAT3. Taken together, bergenin may be a promising candidate for the management of cervical cancer.
View Figures
View References

Related Articles

Journal Cover

May-2019
Volume 17 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shi X, Xu M, Luo K, Huang W, Yu H and Zhou T: Anticancer activity of bergenin against cervical cancer cells involves apoptosis, cell cycle arrest, inhibition of cell migration and the STAT3 signalling pathway Retraction in /10.3892/etm.2021.10085. Exp Ther Med 17: 3525-3529, 2019.
APA
Shi, X., Xu, M., Luo, K., Huang, W., Yu, H., & Zhou, T. (2019). Anticancer activity of bergenin against cervical cancer cells involves apoptosis, cell cycle arrest, inhibition of cell migration and the STAT3 signalling pathway Retraction in /10.3892/etm.2021.10085. Experimental and Therapeutic Medicine, 17, 3525-3529. https://doi.org/10.3892/etm.2019.7380
MLA
Shi, X., Xu, M., Luo, K., Huang, W., Yu, H., Zhou, T."Anticancer activity of bergenin against cervical cancer cells involves apoptosis, cell cycle arrest, inhibition of cell migration and the STAT3 signalling pathway Retraction in /10.3892/etm.2021.10085". Experimental and Therapeutic Medicine 17.5 (2019): 3525-3529.
Chicago
Shi, X., Xu, M., Luo, K., Huang, W., Yu, H., Zhou, T."Anticancer activity of bergenin against cervical cancer cells involves apoptosis, cell cycle arrest, inhibition of cell migration and the STAT3 signalling pathway Retraction in /10.3892/etm.2021.10085". Experimental and Therapeutic Medicine 17, no. 5 (2019): 3525-3529. https://doi.org/10.3892/etm.2019.7380